Skip to main content

Table 1 Baseline characteristics of the study population

From: Real-world long-term outcomes based on three therapeutic strategies in very old patients with three-vessel disease

Variable

PCI (n = 286)

CABG (n = 129)

MT (n = 296)

P value

Age (years)

77.4 ± 2.5

76.8 ± 1.9

77.4 ± 2.5

0.029

Female

92 (32.2)

23 (17.8)

89 (30.1)

0.009

Body mass index (kg/m2)

25.0 ± 3.0

25.1 ± 3.1

24.9 ± 3.0

0.352

Risk factors and comorbidities

    

Hypertension

203 (71.0)

93 (72.1)

212 (71.6)

0.970

Diabetes mellitus

103 (36.0)

42 (32.6)

107 (36.1)

0.750

Previous myocardial infarction

85 (29.7)

50 (38.8)

101 (34.1)

0.176

Hyperlipidemia

123 (43.0)

60 (46.5)

162 (54.7)

0.016

Stroke

38 (13.3)

13 (10.1)

42 (14.2)

0.508

Peripheral artery disease

13 (4.5)

23 (17.8)

28 (9.5)

 < 0.001

Chronic kidney disease

2 (0.7)

2 (1.6)

11 (3.7)

0.031

Smoker

113 (39.5)

56 (43.4)

123 (41.6)

0.738

Clinical presentation

    

Stable angina pectoris

81 (28.3)

51 (39.5)

80 (27.0)

0.027

ACS

205 (71.7)

78 (60.5)

216 (73.0)

0.027

Left main disease

57 (19.9)

66 (51.2)

104 (35.1)

 < 0.001

Left ventricular ejection fraction < 40%

3 (1.0)

2 (1.6)

5 (1.7)

0.797

Creatinine (μmol/L)

89.7 ± 20.6

89.3 ± 17.8

92.5 ± 26.0

0.251

Creatinine clearance (ml/min)

58.6 ± 14.6

60.4 ± 12.9

57.8 ± 16.3

0.256

SYNTAX score

    

≤ 22

135 (47.2)

20 (15.5)

76 (25.7)

 < 0.001

23–32

103 (36.0)

42 (32.6)

108 (36.5)

0.752

≥ 33

47 (16.4)

67 (51.9)

111 (37.5)

 < 0.001

Medication upon discharge

    

Aspirin

275 (96.2)

119 (92.2)

272 (91.9)

0.082

Clopidogrel

256 (89.5)

11 (8.5)

119 (40.2)

 < 0.001

Beta-blockers

242 (84.6)

103 (79.8)

253 (85.5)

0.329

Statins

284 (99.3)

128 (99.2)

295 (99.7)

0.781

Angiotensin converting enzyme inhibitors

277 (96.9)

126 (97.7)

285 (96.3)

0.743

Nitrates

256 (89.5)

117 (90.7)

276 (93.2)

0.271

Calcium channel blockers

278 (97.2)

126 (97.7)

287(97.0)

0.917

  1. ACS acute coronary syndrome